1. Generics Bulletin
  2. >>Products
  3. >>Generics

FDA Approves First Generic Exparel – But What Will The Courts Say?

ANDA Holder eVenus Predicted To Settle; Potential For 2041 US Launch Or Later

 
• By Dean Rudge

Despite the first and only US FDA approval, Jiangsu Hengrui’s US eVenus has been tipped to stay out of the generic Exparel market until at least the end of the 2030s. Generics Bulletin investigates.

Drugs question mark
• Source: Shutterstock

Jiangsu Hengrui’s US eVenus Pharmaceutical Laboratories subsidiary has won US Food and Drug Administration approval for the first generic version of Pacira BioSciences’ Exparel (bupivacaine) liposomal injectable, the long-acting local analgesic for post-surgical pain which brought in sales of nearly $550m last year.

Guarded strongly by demanding bioequivalence guidance and a litany of patents, Exparel has faced almost no threat from generic competition...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By Dean Rudge

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By Dave Wallace

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.